What is the generic name?

COLESTIPOL HYDROCHLORIDE

What is the Trade Name for COLESTIPOL HYDROCHLORIDE?

COLESTIPOL HYDROCHLORIDE

What are the Indications for COLESTIPOL HYDROCHLORIDE?

• INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atheroschlerotic Disease * Two or More Other Risk Factors ‚Ć Initiation Level Goal No No ‚â• 190 (‚â• 4.9) < 160 (< 4.1) No Yes ‚â• 160 (‚â• 4.1) < 130 (< 3.4) Yes Yes or No ‚â• 130 (‚â• 3.4) ‚⧠100 (‚⧠2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ‚Ć Other risk factors for coronary heart disease (CHD) include: age (males: ‚â• 45 years; female: ‚â• 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ‚â• 60 mg/dL (1.6 mmol/L).

References: https://open.fda.gov/